Omnicell Q4 EPS misses estimates

Omnicell

05/02/2026 11:39

Overview

Healthcare technology provider's fiscal Q4 revenue grew 2% yr/yr

Adjusted EPS for fiscal Q4 missed analyst expectations

Company launched Titan XT dispensing system to enhance medication management

Outlook

Omnicell projects 2026 total revenues between $1.215 bln and $1.255 bln

Company expects 2026 annual recurring revenue between $680 mln and $700 mln

Omnicell anticipates 2026 non-GAAP EPS between $1.65 and $1.85

Result Drivers

SERVICE REVENUE GROWTH - Q4 revenue increase driven by technical service offerings and SaaS and Expert Services

CONSUMABLES REVENUE - Increased consumables revenue contributed to Q4 revenue growth

TITAN XT LAUNCH - Launch of Titan XT aimed at enhancing medication management efficiency

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
$314 mln
Q4 Adjusted EPS
Miss
$0.40
$0.50 (8 Analysts)
Q4 Adjusted Net Income
$18 mln
Q4 Net Income
-$2 mln
Q4 Adjusted EBITDA
$37 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Omnicell Inc is $60.00, about 28.5% above its February 4 closing price of $46.69

The stock recently traded at 25 times the next 12-month earnings vs. a P/E of 19 three months ago

Press Release: ID:nBwb5crp6a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)